Rapamycin

Product Name: Rapamycin

Synonyms: AY 22989;23,27-EPOXY-3H-PYRIDO(2,1-C)(1,4)OXAAZACYCLOHENTRIACONTINE;NSC-226080;RAPA;RAPAMUNE;RAPAMYCIN;RAPAMYCIN, STREPTOMYCES HYGROSCOPICUS;RPM

CAS: 53123-88-9

MF: C51H79NO13

MW: 914.18

EINECS: 262-640-9

Product Categories: Active Pharmaceutical Ingredients;Immunosuppressant;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Cytokine signaling;Signalling;API;Chiral Reagents;Heterocycles;Inhibitor;VIVACTIL;antibiotic

mp 183-185°C

Fp 87 °C

storage temp. -20°C

Sensitive Moisture Sensitive/Light Sensitive/Hygroscopic

Chemical Properties White to Off-White Solid

Usage A triene macrolide antibiotic isolated from Streptomyces hygroscopicus. Name derived from the native word for Easter Island, Rapa’Nui. Used as an immunosuppressant; antirestenotic.

Usage A specific mTOR inhibitor with an IC50 of 0.1 nM.

Usage antidepressant

Usage immunosuppressant, antineoplastic; rapamycin

Usage Rapamycin is a triene macrolide discovered in 1995 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapi Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumour and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumour growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.

Usage DDP-4 inhibitor type 2 diabetes therapeutic

Usage Rapamycin is a triene macrolide discovered in 1974 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapa Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumor and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumor growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.